Results 221 to 230 of about 2,234,624 (258)

Increased keratin 80 expression predicts poor prognosis and promotes oxaliplatin resistance in gastric cancer. [PDF]

World J Gastroenterol
Yang B, Cao HX, He YW, Ouyang JJ, Lv M, Li YX, Lu YD.   +6 more
europepmc   +1 more source

Modeling oxaliplatin resistance in colorectal cancer reveals a SERPINE1-based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtype. [PDF]

Cell Death Dis
Wong SQR, Das M, Tenzin K, Shirgaonkar N, Chua H, Chee LX, Sae Yeoh A, Murugiah AA, Chua WY, Theardy MS, Subel EJ, Thangavelu MT, Chan JV, Yap CK, Tan IBH, Tsantoulis P, Tejpar S, Loo JM, DasGupta R.   +18 more
europepmc   +1 more source

Correction: THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K/AKT activation in colorectal cancer. [PDF]

Mol Cancer
Zhou X, Han J, Zuo A, Ba Y, Liu S, Xu H, Zhang Y, Weng S, Zhou Z, Liu L, Luo P, Cheng Q, Zhang C, Chen Y, Shan D, Liu B, Yang S, Han X, Deng J, Liu Z.   +19 more
europepmc   +1 more source

Targeting the <i>ZMYM2-ANXA9</i> Axis with <i>FLT3</i> Inhibitor G749 Overcomes Oxaliplatin Resistance in Colorectal Cancer. [PDF]

Biomedicines
Lin D, Xu Y, Zhan H, Liang Y, Liu R, Liu J, Luo D, Chen X, Cai J, Zou Y.   +9 more
europepmc   +1 more source

Correction: PARP1 inhibitor combined with oxaliplatin efficiently suppresses oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway. [PDF]

Front Cell Dev Biol
Li H, Wang C, Lan L, Wu W, Evans I, Ruiz EJ, Yan L, Zhou Z, Oliveira JM, Reis RL, Hu Z, Chen W, Behrens A, He Y, Zhang C.   +14 more
europepmc   +1 more source

Mechanical forces inducing oxaliplatin resistance in pancreatic cancer can be targeted by autophagy inhibition. [PDF]

Commun Biol
Kalli M, Mpekris F, Charalambous A, Michael C, Stylianou C, Voutouri C, Hadjigeorgiou AG, Papoui A, Martin JD, Stylianopoulos T.   +9 more
europepmc   +1 more source

[Tumor-secreted dentin sialophosphoprotein induces oxaliplatin resistance in colorectal cancer through an integrin αvβ3-dependent pathway]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
Liu C, Ning Z, Wu J, Liu W, Lin C, Xu J, Zhou R, Zhao L.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The cellular pharmacology of oxaliplatin resistance

European Journal of Cancer, 2002
Oxaliplatin is a third generation platinum compound that differs from cisplatin and carboplatin in having a broader spectrum of antitumour activity. Molecular studies suggest that oxaliplatin adducts are recognised and processed differently than those produced by the earlier generation Pt-containing drugs.
Stephen B Howell, S B Howell, A Kondo
exaly   +3 more sources

In vitro studies on the mechanisms of oxaliplatin resistance

Cancer Chemotherapy and Pharmacology, 2001
We have previously reported that elevation of glutathione mediated by gamma-glutamyl transpeptidase is one mechanism of oxaliplatin resistance. This study explored other potential oxaliplatin resistance mechanisms with two aims: (1) to identify the differences between cisplatin and oxaliplatin in terms of drug accumulation, DNA-Pt adduct formation and ...
Suzanne Hector, Lakshmi Pendyala
exaly   +3 more sources

Txr1: an important factor in oxaliplatin resistance in gastric cancer

Medical Oncology, 2013
Oxaliplatin-based chemotherapy is the main treatment regimen for gastric cancer (GC), but can fail because of drug resistance. We investigated the role of a recently identified drug-resistance gene, taxol-resistant gene 1 (Txr1), in oxaliplatin resistance. A retrospective study based on banked tissue was carried out.
Zhongtao Zhang, Zhi-Gang Bai, Xin Yi
exaly   +3 more sources